The Anlon Healthcare IPO has entered its final day of bidding, with investors showing interest despite the overall volatility in the Indian equity market. The Rs 121 crore IPO was opened on August 26 and will close today, with expected allotment on September 1, 2025, and a tentative listing date of September 3, 2025.
According to market trackers, shares of Anlon Healthcare are trading at a premium of Rs 6 in the grey market on Day 3, unchanged from the previous day. This indicates a limited listing gain of around 6-7% at the upper price band of Rs 91 per share.
The Anlon IPO GMP provides insights into grey market performance ahead of listing. The GMP reflects cautious market expectations. Even with the stock market correction, the grey market price has remained stable, reflecting confidence based on the subscription numbers.
Market watchers monitor the Anlon IPO Subscription Status to gauge investor demand. By 10:00 AM on the final bidding day, the IPO was subscribed 3.92 times overall. The issue has clearly been retail-driven, with small investors aggressively bidding for shares:
Retail Investors: 26.78x subscribed
Non-Institutional Investors (NIIs): 3.22x subscribed
Qualified Institutional Buyers (QIBs): 1.01x subscribed
By Day 2, the IPO had seen overall subscriptions of 3.3 times, with 22.3 times from retail, 2.09 times from NII, and QIBs surpassing the 1x mark. This momentum has continued into Day 3, and Anlon is likely to be one of the more popular offerings in recent weeks.
Sachin Jasuja of Centricity WealthTech said, "The space of API production is facing tailwinds due to 'Make in India' and Production Linked Incentive (PLI) schemes, which are driving domestic investment into API manufacturing and R&D, helping reduce import dependence and boost local capabilities. Policy support provides a cushion for API manufacturers through subsidies, capex support, and easier regulatory pathways, stimulating growth and improving margin stability.”
An Anlon Healthcare IPO Review helps investors assess risks and growth potential. Shivani Nyati with Swastika Investmart mentions that Anlon is the first Indian manufacturer of Loxoprofen formulations, globally compliant, but is susceptible to operational risks.
The company relies on a single facility in Rajkot, Gujarat, and faced revenue headwinds in FY24 due to registration delays in Brazil. Current IPO valuations seem fully priced, leaving little room for aggressive listing gains.
Also Read: Amanta Healthcare IPO: Price Band, Lot Size, Subscription Dates & Key Details
IPO Size: Rs 121.03 crore
Price Band: Rs 86-Rs 91 per share
Lot Size: 164 shares
Subscription (Day 3): 3.92x overall
GMP: Rs 6
Allotment Date: September 1, 2025
Tentative Listing Date: September 3, 2025
The Anlon Healthcare IPO has received impressive subscription numbers, particularly from retail investors, indicating strong demand from investors. However, the flat GMP suggests limited listing gains in the near term.
Traders await the official Anlon IPO Allotment Date to check share allocations. The IPO is seeing robust demand but cautious listing expectations. Retail investors may consider applying with a long-term perspective, while short-term players should temper expectations of big listing gains.